One therapeutic dose of radiation causes 30 percent spongy bone loss in mice

July 12, 2006

Bethesda, MD. (July 12, 2006) - Mice receiving just one therapeutic dose of radiation lost up to 39% of the spongy portion of their inner bone, reducing the inner bone's weight bearing connections by up to 64%, researchers reported. The study, which appears in the online edition of the Journal of Applied Physiology, has implications for patients receiving radiation therapy and astronauts traveling on long space flights.

"We were really surprised at the extent of bone loss," said lead researcher Ted A. Bateman of Clemson University. "We're seeing bone loss at much lower doses of radiation than we expected." The mice suffered the loss of trabecular bone, the spongy area of bone inside the dense outer area known as the cortical bone.

"It's interesting that the trabecular bone, not the cortical bone, suffered the damage," said Bateman, a bioengineer who studies bone biomechanics. The remaining spongy bone must redistribute the load to bear the weight, but this makes the bone support structure less efficient and leaves the bone more vulnerable to fracture.

"A murine model for bone loss from therapeutic and space-relevant sources of radiation," by Sarah A. Hamilton, Neil D. Travis, Jeffrey S. Willey, Eric R. Bandstra and Ted A. Bateman, Clemson University; and Michael J. Pecaut, Daila S. Gridley and Gregory A. Nelson, Loma Linda University and Medical Center, appears in the online edition of the Journal of Applied Physiology, published by The American Physiological Society.

Mouse model applies to humans

The results of a mouse study cannot be directly applied to humans. However, both mice and humans lose bone after radiation exposure, so the results raise a red flag. Bateman noted that a recent clinical study of 6,000 cancer patients reported in the Journal of the American Medical Association found that post-menopausal women who received pelvic radiation for cervical and colorectal cancer increased their bone fracture risk by 60%. Radiation following anal cancer increased the risk of fracture by 200%, he said.

Astronauts lose 2% of bone mass for each month they are exposed to the effects of microgravity. So far, astronauts have not been exposed to the increased radiation of outer space, but that will change when they undertake a proposed 30-month trip to Mars, Bateman said. NASA has focused on radiation's cancer-causing properties and its ability to compromise the central nervous and immune systems. But the effect on bone health is an unexamined concern.

The murine (mouse) model such as the one in this study provides a way to study the physiological effects of radiation using controlled experiments. Clinical studies of people who undergo radiation to treat cancer are limited because of the complicating factors of the illness itself and the chemotherapy which often accompanies it. "You can't study this in people, so having a well-defined animal model is important," Bateman said.

Study focuses on four types of radiation

In the current study, the mice received a single 2 Gray (Gy) dose, which is comparable to the single dose of 1-2 Gy that human cancer patients receive. However, cancer patients receive a series of doses over the course of therapy, totaling 10-70 Gy. (The amount of radiation in a Gy varies, because it is calculated based on the recipient's weight.)

The mice were divided into five groups. The control group received no radiation. Each of the remaining four groups received a different type of radiation: gamma, proton, ion or carbon. Those exposed to the carbon radiation suffered 39% spongy bone loss; proton, 35%; ion, 34%; and gamma, 29%. The loss of spongy connections in the four groups ranged from 46-64%, he said.

Cancer patients typically receive either gamma or, less commonly, proton radiation. Astronauts on a Mars mission are expected to receive extended periods of low-dose radiation of multiple types, including protons and heavy ions, Bateman said.


"A murine model for bone loss from therapeutic and space-relevant sources of radiation," by S.A. Hamilton, N.D. Travis, J.S. Willey and T.A. Bateman, Department of Bioengineering, Clemson University, Clemson, South Carolina; M.J. Pecaut, D.S. Gridley and G.A. Nelson, department of Radiation Medicine, Loma Linda University and Medical Center, Loma Linda, California, appears in the online edition of the Journal of Applied Physiology published by The American Physiological Society.

Bateman's team received the mouse bones from the Loma Linda group, which had used the mice to examine the effects of radiation on the immune system.
Procter and Gamble Pharmaceuticals, the National Space Biomedical Research Institute and NASA provided grants to fund this research.

Editor's notes:
Bateman will be at the Kennedy Space Center and available for interviews July 13-17 to give a presentation to university undergraduate students spending the summer at the Spaceflight and Lunar Sciences Technology Program.

The media may obtain a copy of Hamilton et al. by contacting Christine Guilfoy, American Physiological Society, (301) 634-7253 or

The American Physiological Society was founded in 1887 to foster basic and applied bioscience. The Bethesda, Maryland-based society has 10,500 members and publishes 14 peer-reviewed journals containing almost 4,000 articles annually.

APS provides a wide range of research, educational and career support and programming to further the contributions of physiology to understanding the mechanisms of diseased and healthy states. In 2004, APS received the Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring (PAESMEM).

American Physiological Society

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to